Notice2025-00454

Agency Forms Undergoing Paperwork Reduction Act Review

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published
January 13, 2025

Issuing agencies

Health and Human Services DepartmentCenters for Disease Control and Prevention

Full Text

<html>
<head>
<title>Federal Register, Volume 90 Issue 7 (Monday, January 13, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 7 (Monday, January 13, 2025)]
[Notices]
[Pages 2704-2706]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-00454]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day-25-1385]


Agency Forms Undergoing Paperwork Reduction Act Review

    In accordance with the Paperwork Reduction Act of 1995, the Centers 
for Disease Control and Prevention (CDC) has submitted the information 
collection request titled ``Characteristics of Cases of Priority Fungal 
Diseases'' to the Office of Management and Budget (OMB) for review and 
approval. CDC previously published a ``Proposed Data Collection 
Submitted for Public Comment and Recommendations'' notice on October 
25, 2024, to obtain comments from the public and affected agencies. CDC 
did not receive comments related to the previous notice. This notice 
serves to allow an additional 30 days for public and affected agency 
comments.

[[Page 2705]]

    CDC will accept all comments for this proposed information 
collection project. The Office of Management and Budget is particularly 
interested in comments that:
    (a) Evaluate whether the proposed collection of information is 
necessary for the proper performance of the functions of the agency, 
including whether the information will have practical utility;
    (b) Evaluate the accuracy of the agencies estimate of the burden of 
the proposed collection of information, including the validity of the 
methodology and assumptions used;
    (c) Enhance the quality, utility, and clarity of the information to 
be collected;
    (d) Minimize the burden of the collection of information on those 
who are to respond, including, through the use of appropriate 
automated, electronic, mechanical, or other technological collection 
techniques or other forms of information technology, e.g., permitting 
electronic submission of responses; and
    (e) Assess information collection costs.
    To request additional information on the proposed project or to 
obtain a copy of the information collection plan and instruments, call 
(404) 639-7570. Comments and recommendations for the proposed 
information collection should be sent within 30 days of publication of 
this notice to <a href="http://www.reginfo.gov/public/do/PRAMain">www.reginfo.gov/public/do/PRAMain</a>. Find this particular 
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct 
written comments and/or suggestions regarding the items contained in 
this notice to the Attention: CDC Desk Officer, Office of Management 
and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202) 
395-5806. Provide written comments within 30 days of notice 
publication.

Proposed Project

    Characteristics of Cases of Priority Fungal Diseases (OMB Control 
No. 0920-1385, Exp. 4/30/2027)--Revision--National Center for Emerging 
and Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control 
and Prevention (CDC).

Background and Brief Description

    Fungal diseases cause substantial illness, ranging from mild 
infection to severe or life-threatening invasive disease. They also 
constitute a considerable financial burden on patients and healthcare 
systems. Awareness of fungal diseases is low, and data collection has 
historically been limited in size, scope, and coordination, which has 
hindered our understanding of these diseases. Detailed epidemiologic 
and clinical data are critical to inform appropriate public health 
responses. We plan to enhance surveillance of high priority fungal 
diseases across the United States to better characterize factors such 
as disease burden, geographic scope, patient risk factors, health 
disparities, healthcare utilization, outcomes, and emerging trends. 
This project will serve as a Revision of the information collections 
project: Characteristics of Cases of Priority Fungal Diseases Case 
Report Form (CRF) (OMB Control No. 0920-1385). The Revision will expand 
the number of fungal diseases for which data may be collected.
    In addition to triazole-resistant A. fumigatus infections, 
coccidioidomycosis, histoplasmosis, blastomycosis, C. auris, and 
antifungal-resistant dermatophytosis, CRFs have also been developed for 
chromoblastomycosis, mycetoma, and sporotrichosis. We plan to use 
standardized CRFs to collect public health surveillance data for cases 
of these diseases regarding demographics (e.g., age, sex, race/
ethnicity, location of residence), underlying medical conditions, 
diagnosis (e.g., clinical presentation, laboratory testing), 
treatments, and outcomes (e.g., hospitalization, vital status). The 
corresponding CRF would be filled out voluntarily by State, local or 
Tribal health departments, Federal agencies, and the members of the 
private sector (e.g., academic institutions) and contains a section for 
medical chart review and an optional supplemental interview (including 
data on potential occupational or environmental exposures) of the 
patient or their representative.
    Findings can help identify populations at higher risk of these 
diseases, detect emerging epidemiologic trends, and guide prevention 
and response efforts. They can also help better focus public and 
healthcare provider outreach, inform efforts to contain or mitigate 
spread, and influence health policy and research on prevention and 
treatment.
    CDC requests OMB approval for an estimated 1,564 annual burden 
hours. There is no cost to respondents other than their time to 
participate.

                                        Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
                                                                                      Number        Avg. burden
               Form name                   Type of respondent        Number of     responses per   per response
                                                                    respondents     respondent       (in hrs.)
----------------------------------------------------------------------------------------------------------------
Triazole-resistant Aspergillus          State and Local Health                15              15             0.5
 fumigatus Case Report Form              Departments.
 (Attachment 3a).
Coccidioidomycosis Case Report Form     State and Local Health                10              25             1.0
 (Attachment 3b).                        Departments.
                                        Private Sectors.........               3              10             1.0
Histoplasmosis Case Report Form         State and Local Health                10              25             1.0
 (Attachment 3c).                        Departments.
                                        Private Sectors.........               3              10             1.0
Blastomycosis Case Report Form          State and Local Health                10              25             1.0
 (Attachment 3d).                        Departments.
                                        Private Sectors.........               3              10             1.0
Candida auris Case Report Form          State and Local Health                15              20            0.75
 (Attachment 3e).                        Departments.
                                        Private Sectors.........               3              10            0.75
Antifungal-resistant dermatophytosis    State and Local Health                10              10             0.5
 case report form (Attachment 3f).       Departments.
Chromoblastomycosis case report form    Private Sectors.........              25              10             0.5
 (Attachment 3g).
Mycetoma case report form (Attachment   Private Sectors.........              25               5             0.5
 3h).
Sporotrichosis case report form         Private Sectors.........              25              10             0.5
 (Attachment 3i).
----------------------------------------------------------------------------------------------------------------



[[Page 2706]]

Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Public Health 
Ethics and Regulations, Office of Science, Centers for Disease Control 
and Prevention.
[FR Doc. 2025-00454 Filed 1-10-25; 8:45 am]
BILLING CODE 4163-18-P


</pre></body>
</html>
Indexed from Federal Register on January 13, 2025.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.